Europe's Cannabis Market Set for Sustained Growth Through 2030

A Market Taking Shape, Unevenly

Europe's cannabis sector is entering what analysts are describing as a sustained growth phase, with projections pointing to significant market expansion through 2030 across both medical and — where permitted — adult-use segments. The trajectory, however, is anything but uniform. Regulatory divergence between member states remains the single largest structural variable, and the gap between countries advancing comprehensive frameworks and those still treating cannabis as a largely prohibited substance continues to widen.

According to analysis published by MarketsandMarkets, the European cannabis market is positioned for considerable growth over the coming years, driven by increasing patient access to medical cannabis, gradual liberalisation in selected jurisdictions, and growing infrastructure investment from licensed producers and pharmaceutical-adjacent companies. The report stops short of projecting a unified European market — because no such thing yet exists — but the directional consensus is clear: capital and regulatory intent are converging.

Medical Cannabis as the Load-Bearing Pillar

Medical cannabis continues to account for the dominant share of regulated cannabis revenue across Europe. Germany remains the most watched market following its 2024 partial legalisation framework, which, while more restricted than initially proposed, nonetheless signalled a meaningful shift in political acceptability within the EU's largest economy. Countries including the Netherlands, Denmark, Portugal, and increasingly Italy have expanded or are in the process of expanding their medical cannabis programmes, creating incremental demand that domestic and import-dependent supply chains are scrambling to meet.

The pharmaceutical channel — formal prescriptions dispensed through licensed pharmacies — is growing, though patient access barriers remain significant in many markets. Cost coverage through national health systems is inconsistent, and prescribing clinicians in several countries continue to report limited training and institutional hesitancy around cannabis-based medicines. These friction points are constraining growth in the near term even as the regulatory scaffolding improves.

Supply Infrastructure and the Import Dynamic

Europe's cannabis supply remains heavily dependent on imports, predominantly from Canadian licensed producers, Australian exporters, and a growing number of Southern Hemisphere suppliers. Domestic cultivation is expanding in countries like Portugal, North Macedonia, and Denmark, but large-scale EU-based production capable of meeting forecast demand at competitive price points remains underdeveloped.

This import dependency has implications not only for supply security but for pricing. As pharmaceutical-grade cannabis products are subject to Good Manufacturing Practice (GMP) certification requirements across most European markets, production costs remain elevated — a factor that analysts identify as a persistent drag on consumer affordability and, by extension, market volume.

The Regulatory Patchwork Problem

Perhaps the most consequential insight from a market-structure perspective is how deeply regulatory fragmentation is shaping investment and growth patterns. Operators looking to build pan-European businesses face a landscape in which licensing, THC limits, product categories, and distribution rules vary not just country by country, but sometimes between product types within the same jurisdiction.

The absence of a harmonised EU-level framework for medical cannabis — let alone adult use — means that companies must essentially build market-entry strategies on a country-by-country basis. This raises compliance costs, extends go-to-market timelines, and concentrates investment in a handful of more predictable jurisdictions. Smaller or newer markets, including Malta, find themselves in an interesting position: a functioning regulatory architecture exists, but the addressable patient population is modest and the broader adult-use framework is nascent relative to larger European peers.

Where Malta Sits in the Broader Picture

Malta's position in this market context is instructive. As one of the first EU member states to legalise adult cannabis use and establish a regulated non-commercial framework through the Authority on the Responsible Use of Cannabis (ARUC), the island holds a degree of policy credibility that outstrips its market size. ARUC's model — centred on non-profit Cannabis Harm Reduction Associations (CHRAs) rather than commercial retail — sits outside the commercial market paradigm that most industry analysts are modelling. That is not a weakness, but it does mean Malta will not register meaningfully in revenue-focused projections.

What Malta does offer, in the context of European market development, is a template for harm reduction-oriented regulation that sits alongside, rather than in opposition to, medical access infrastructure. Whether that model influences neighbouring Mediterranean jurisdictions — particularly as Italy and France continue to debate their own frameworks — remains one of the more interesting policy questions of the next several years.

The Decade Ahead

Market projections are inherently imprecise instruments, particularly in a sector where a single regulatory decision in a large member state can materially reshape the competitive landscape overnight. What the available analysis does confirm is that European cannabis — as a medical, regulatory, and eventually commercial phenomenon — is no longer a niche conversation. The infrastructure is being built, patient familiarity is growing, and institutional capital is paying attention.

The question is less whether the market will grow and more who will be positioned to benefit when the remaining regulatory dominoes fall.

Sources:
MarketsandMarkets — Europe Cannabis Market Size, Share, Trends, Growth Analysis Report, 2030

Featured image: Photo by Ieva Brinkmane on Pexels